Ibex Investors’s AbbVie ABBV Stock Holding History

Ibex Investors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,086	Closed	-$292K	–	154
2018 Q1	$292K	Buy	+3,086	New	+$339K	0.24%	144

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Ibex Investors's ABBV Position: Q2 2018 in Review

Ibex Investors sold out of AbbVie (ABBV) in Q2 2018, closing a stake of 3,086 shares — an estimated $292K sold.

Ibex Investors first reported a position in ABBV in Q1 2018 and held it in 1 quarter. The position peaked at $292K in Q1 2018. 1,997 funds tracked by Wall St. Rank hold ABBV as of Q2 2018.

Ibex Investors reported no remaining AbbVie position as of Q2 2018 after selling out during the quarter.
Ibex Investors sold 3,086 AbbVie shares in Q2 2018, an estimated $292K.
Ibex Investors first reported a position in AbbVie in Q1 2018 and held it in 1 quarter.
Ibex Investors's AbbVie position peaked at $292K in Q1 2018.
1,997 funds tracked by Wall St. Rank held AbbVie as of Q2 2018.

Based on Ibex Investors's 13F filing for Q2 2018, filed 14 Aug 2018.